It is not easy to turn around a struggling medical technology business. It took a while for Covidien (COV) to really get back into the swing of things, and Johnson & Johnson (JNJ) still has a way to go, but those companies pale in comparison to the challenges at Boston Scientific (BSX).
While this quarter was not a disaster, and the company does have some
valid opportunities in its pipeline, it just feels like the newsflow
from this company has been unrelentingly disappointing for quite a while
now.
Read more here:
How Can Boston Scientific Still Be This Bad?
No comments:
Post a Comment